The Polarix Trial: Initial Therapy of Diffuse Large B-cell Lymphoma

This Harvard Medical School Continuing Education video examines these key questions: What is the current standard of care for diffuse large B-cell lymphoma (DLBCL). What is the significance of the Polarix trial in understanding DLBCL?

Dr. Connor Johnson, MD, an oncologist at Massachusetts General Hospital, reviews the RCHOP standard of care for diffuse large B-cell lymphoma patients and introduces the question of how the drug polatuzumab vedotion may apply to the treatment of DLBL, a question addressed by the Polarix trial. Dr. Johnson identifies the patient characteristics of trial participants and summarizes important outcomes and key takeaways from the Polarix trial.

00:00 | Introduction
00:37 | The R-CHOP standard of care
01:24 | What kind of drug is polatuzamab vedotin?
01:58| The Polarix trial
04:03 | Key Takeaways

This video was peer reviewed by Dr. Jonathan Salik, TMD, MHPEd, Instructor of Medicine, Massachusetts General Hospital; and Dr. Sugantha Sundar, MD, Assistant Professor of Anesthesia, Beth Israel Deaconess Medical Center, to validate the quality and accuracy of the content. It was edited by affiliate physicians of Harvard Medical School, Arielle J Medford, MD, Senior Medical Oncology Fellow, Dana-Farber Cancer Institute and Anna Handorf, MD, Research Fellow in Pediatrics, Massachusetts General Hospital.

References:
Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017;35(31):3529-3537. doi:10.1200/JCO.2017.73.3402

Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2020;38(2):155-165. doi:10.1200/JCO.19.00172

Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304

Notice: At this time, the content in this video is not accredited.